The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders

Klausen, Mette Kruse, Thomsen, Morgane, Wortwein, Gitta, Fink‐Jensen, Anders·2022·British Journal of Pharmacology

DOI 10.1111/bph.15677

Cited by (258)

Items 101–200 of 258

A Brain Reward Circuit Inhibited By Next-Generation Weight Loss Drugs
Elizabeth Godschall, Taha Buğra Güngül, Isabelle R. Sajonia, Aleyna K. Buyukaksakal, Orien Dong-Ang Li, Sophia Ogilvie, Austin B. Keeler, Guilian Tian, Omar Koita, Yu Shi et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
Biological basis of addiction and alcohol use disorder
Ryan E. Tyler, Lorenzo Leggio · 2024 · Clinical Liver Disease
Connecting the dots: Understanding and addressing the metabolic impact of antipsychotic and antidepressant medications
Susanne U. Miedlich, J. Steven Lamberti · 2025 · Annals of the New York Academy of Sciences
Effect of the GLP ‐1 receptor agonist exenatide on pro‐inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double‐blinded, placebo‐controlled clinical trial
Malthe E. B. Hviid, Lea Arregui Nordahl Christoffersen, Mette Kruse Klausen, Thorsten Brodersen, Ole Birger Pedersen, Sisse Rye Ostrowski, Margit Hørup Larsen, Mette Kongstad, Mathias Ebbesen Jensen, Tina Vilsbøll et al. · 2025 · Alcoholism Clinical and Experimental Research
Once-Weekly Semaglutide in Adults With Daily Cigarette Use
Christian S. Hendershot, Michael P. Bremmer, Michael B. Paladino, Georgios Kostantinis, Thomas A. Gilmore, Neil R. Sullivan, Amanda C. Tow, Mark A. Prince, Sarah Siodmok Dermody, Robyn Jordan et al. · 2026 · JAMA Network Open
Emerging pharmacological targets for alcohol use disorder
Dakota F. Brockway, Nicole A. Crowley · 2024 · Alcohol
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies
Arthi Palani, Sagar Patel, Shriya Patel, Shivani Srivastava, Jay Patel, Salman Salehin, Yochai Birnbaum, Joseph Allencherril · 2025 · Cardiovascular Drugs and Therapy
Molecular Effect of Tobacco on Genetic, Epigenetic, and Metabolic Pathways During Cancer Progression
Ujjwal Kumar, G Jahnavi, Bijit Biswas, Benazir Alam, Saurabh Varshney · 2026 · Cureus
Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity: a nested case-control study in the All of Us research program
Tadesse Melaku Abegaz, Muktar Beshir Ahmed, Akshaya Srikanth Bhagavathula, Gabriel A. Frietze · 2026 · Frontiers in Psychiatry
Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation
Christian S. Hendershot, W. Kyle Simmons, Manish K. Jha, Sherry A. McKee, Luba Yammine · 2026 · Biological Psychiatry
Approved, Promising, and Experimental Medications for Treatment of Alcohol Use Disorder
András H. Lékó, Mehdi Farokhnia, Lorenzo Leggio · 2023 · Springer eBooks
Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?
Rodrigo Barbachan Mansur, Joshua D. Di Vincenzo, Sebastian Badulescu, Hartej Gill, Aniqa Tabassum, Cristian-Daniel Llach, Joshua Daniel Rosenblat, Roger S. McIntyre · 2024 · CNS Spectrums
The Combined Effect of Smoking and Obesity on Hypertension: Implications for Clinical Management
Dimitrios Aragiannis, Alexandros Kasiakogias, Panagιotis Iliakis, Μarios Sagris, Fotios Panagiotis Tatakis, Eleni Manta, Ioannis Andrikou, Dimitrios Konstantinidis, Konstantinos P Tsioufis · 2025 · Current Hypertension Reviews
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Timothy D. Roberts, Dana S. Hutchinson, Denise L. Wootten, Miles J. De Blasio, Rebecca Helen Ritchie · 2025 · Journal of Molecular and Cellular Cardiology
Contribution of Visceral Systems to the Development of Substance Use Disorders: Translational Aspects of Interaction between Central and Peripheral Mechanisms
Danil Peregud, Natalia V. Gulyaeva · 2024 · Biochemistry (Moscow)
Addressing the dual challenge: Managing smoking cessation in patients with diabetes
Cristina Russo, Magdalena Walicka, Gal A. Cohen, Carlo Maria Bellanca, Giulio Geraci, Pasquale Caponnetto, Dario Elvio Noviello, Roberta Chianetta, Jacob George, Roberta Sammut et al. · 2025 · World Journal of Diabetes
Real‐World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP ‐1 Receptor Agonists Versus FDA ‐Approved AUD Medications
Amir Gougol, Paul Yien Kwo, William Pike, Mehdi Farokhnia, Gavin Hui, Saurabh Gombar, Babak Mirminachi · 2026 · Alimentary Pharmacology & Therapeutics
Association of Glucagon‐Like Peptide‐1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Shumeng Han, Yucheng Yang, Zijun Liu, Yiwen Liu, Baodi Xing, Xuechen Wang, Jie Yu, Fan Ping, Wei Li, Lingling Xu et al. · 2026 · Diabetes Obesity and Metabolism
Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents
Christian E. Edvardsson, Xinming Zhang, Thaynnam Arcebispo Emous, Louise Adermark, Sarah Witley, Mia Ericson, Heath D. Schmidt, Elisabet Jerlhag · 2026 · EBioMedicine
Novel potential pharmacological approaches in treating eating disorders comorbid with substance use disorders
Zheng‐Xiong Xi, Ewa Galaj · 2025 · Biomedicine & Pharmacotherapy
Liraglutide alleviated alpha-pyrrolidinovalerophenone (α-PVP) induced cognitive deficits in rats by modifying brain mitochondrial impairment
Marzieh Noruzi, Homayoon Behmadi, Omid Sabzevari, Alireza Foroumadi, Mohammad Hossein Ghahremani, Jalal Pourahmad, Shokoufeh Hassani, Maryam Baeeri, Mahdi Gholami, Amirhosein Ghahremanian et al. · 2024 · European Journal of Pharmacology
Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review
Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel Leonard Chan · 2024 · Metabolism and Target Organ Damage
How to treat antipsychotic‐related weight gain and metabolic disturbances: Is there a role for GLP ‐1 receptor agonists?
Anders Fink‐Jensen, Christoph Ulrich Correll · 2024 · Acta Psychiatrica Scandinavica
Beyond Glycemic Control: GLP-1RA–Based Therapies and Emerging Targets Beyond the Metabolic Axis
Wojciech Matuszewski, Katarzyna Wołos-Kłosowicz, Paulina Włodarczyk, Patrycja Waśniewska, Robert Modzelewski, Jan Marek Górny, Michał Szklarz, Mikołaj Madeksza, Judyta Karolina Juranek · 2026 · Journal of Clinical Medicine
The Role of Gut Microbiome in Obesity and Weight Management: A Review of Current Evidence and Future Directions
Abdul Rehman, Noman Ali, Muhammad Rizwan Tariq, Shinawar Waseem Ali, Azeem Mushtaq, Waseem Safdar, Abdikhaliq Mursal Yusuf · 2026 · Food Science & Nutrition
Emerging Therapeutics in the Treatment of Substance Use Disorders: A Focus on GLP-1 Receptor Agonists, D3R Antagonists, and CRF Antagonists
Khaled Draghmeh, Brian Fuehrlein · 2025 · Journal of Integrative Neuroscience
Treatment of diabetes in patients with advanced chronic kidney disease or kidney failure
George C. Bonifant, Stephen N. Davis, Matthew R. Weir · 2025 · Nephrology Dialysis Transplantation
Modeling the genomic architecture of adiposity and anthropometrics across the lifespan
Christopher H. Arehart, Meng Hsuan Lin, Raine A Gibson, Heather D. Anderson, Aquilante CL, Kelsey L. Arbogast, Christopher H. Arehart, Ian M. Brooks, Tonya M. Brunetti, Judith Brutus-Lestin et al. · 2025 · Nature Communications
Semaglutide for Craving Reduction in a Cocaine Dependent Patient: A Case Report
Alessandro Matteo Sileoni, Elena Teresa Turco, Francesco Semeraro, Clara Cavallotto, Alessio Mosca, Stefania Chiappini, Giovanni Martinotti · 2025 · Clinical Neuropsychopharmacology and Addiction
Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System
José Seijas‐Amigo, Ángel Salgado‐Barreira, Diego Rodríguez‐Penas, Begoña Cardeso-Paredes, Marta Ribeiro-Ferreiro, Moisés Rodríguez‐Mañero, JR González-Juanatey · 2026 · International Journal of Clinical Pharmacy
Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26‐week open‐label feasibility study
Marie Reeberg Sass, Anne Mette Brandt Christensen, Margit Lykke Christensen, Ema Nicea Gruber, Helle Nerdrum, Lone Marianne Pedersen, Maximilian Resch, Troels Højsgaard Jørgensen, Claus Thorn Ekstrøm, Jimmi Nielsen et al. · 2024 · Acta Psychiatrica Scandinavica
Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes
Maxwell Salvatore, Bingyu Zhang, Huilin Tang, Yiwen Lu, Dazheng Zhang, Ting Zhou, Yuan Lu, Anastassia Amaro, Marylyn DeRiggi Ritchie, Yong Chen · 2025 · medRxiv
Sweet Taste Receptors’ Genetic Variability in Advanced Potential Targets of Obesity
Sonia Wagner, Lara Paula Fernández, Gonzalo Colmenarejo, Silvia Cruz-Gil, Isabel Espinosa‐Salinas, Susana Molina, María Carmen Crespo, Elena Aguilar-Aguilar, Helena Marcos-Pasero, Rocío de la Iglesia et al. · 2025 · Nutrients
Trends in Newly Filled GLP-1 Receptor Agonist Prescriptions for US Patients With Versus Without Comorbid Alcohol Use Disorder, 2016–2024
Joshua David Wallach, Stephanie S. O’Malley, Kasia J. Lipska, Joseph S. Ross, Molly M. Jeffery, Samuel Thomas Savitz · 2025 · Journal of Addiction Medicine
National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss
Jordan Miller, Robert Miller, Shawn M. Varney, David C. Han · 2026 · Journal of Medical Toxicology
Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patients
Soo Young Hwang, Pinghsin Hsieh, Luis Antonio Díaz, Russell P. Goodman, Esperance A. K. Schaefer, Robert J. Wong, Jay Luther, Wei Zhang · 2026 · European Journal of Gastroenterology & Hepatology
Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats
Stephen E. Chang, Christopher A. Turner, Natalia Morales Pagan, Daniela Pereira, Sophia Ines Kleer, Shelly B. Flagel · 2026 · Psychopharmacology
The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis
Kezia Peter, Ocin Roka, Emma Sepp, Maya Warburton, Jufen Zhang, Simon C. Cork · 2026 · Cardiovascular Diabetology – Endocrinology Reports
Novel Pharmacological Agents for the Treatment of Cocaine Use Disorder
Hasti Hadizadeh, José M. Flores, Eric J. Nunes, Talia F. Mayerson, Marc Nicholas Potenza, Gustavo A. Angarita · 2022 · Current Behavioral Neuroscience Reports
Gender differences in weight gain during attempted and successful smoking cessation on dulaglutide treatment: a predefined secondary analysis of a randomised trial
Fabienne Baur, Cihan Atila, Sophia Lengsfeld, Thilo Burkard, Andrea Meienberg, Cemile Bathelt, Mirjam Christ‐Crain, Bettina Felicitas Winzeler · 2023 · BMJ Nutrition Prevention & Health
GLP-1 Receptor Agonists: Beyond Diabetes—What the Neurosurgeon Needs to Know
Hael Abdulrazeq, Mazen Taman, Rohaid Ali, Cody Doberstein, Patricia Zadnik Sullivan, Prakash Sampath, Albert Edward Telfeian, Ziya Levent Gokaslan, Jared Fridley, Wael F. Asaad · 2024 · Neurosurgery Open
Hypothesizing glucagon-like peptide 1 (GLP-1), agonists promote hypodopaminergia, resulting in heightened addictive reward-seeking and altered mood: Breaking the bubble and adding salt to a wound
Kenneth Blum, Catherine A. Dennen, Kai-Uwe Lewandrowski, Alireza Sharafshah, Albert Pinhasov, Abdalla Bowirrat, Igor Elman, Jean Lud Cadet, Eric R. Braverman, Panayotis K. Thanos et al. · 2025 · Medical Hypotheses
Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder
Tyler Oesterle, Ming‐Fen Ho · 2025 · Brain Sciences
Navigating the Evolving Roles of GLP-1 Agonists Safely and Effectively
Kyle M. Ockerman, Heather J. Furnas, Amy Sheer, Sarah C. Sorice-Virk · 2024 · Aesthetic Surgery Journal
Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder
Tingting Liu, Fuqiang Shi, Zhihua Guo, Hongwu Li, Di Qin · 2025 · Pharmacopsychiatry
Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats
McKinley Windram, Dennis F. Lovelock, Joseph M. Carew, Caroline G Krieman, Christian S. Hendershot, Joyce Besheer · 2025 · Psychopharmacology
Assessment of the Potential of GLP-1 Analogs in the Treatment of Addictions: A Literature Review
Isabel Noemi Torres, Maria Jimena Barroso Alverde · 2025 · Substance Use &amp Addiction Journal
Managing schizophrenia with affective, sexual, metabolic and substance-use comorbidities: pharmacological considerations from an expert consensus
Eduard Vieta, Ángel Montejo, Toby Pillinger, Bernardo Maria Dell’Osso, Maria Dimitraka, Saeed Farooq, Gustavo Jesús, Carlos Parro-Torres, Thomas Wobrock, Sofia Pappa · 2025 · Annals of General Psychiatry
Incretin-Based Therapies: A Novel Pathway in Addiction Treatment
Dawid Rosiejka, Michałowska Joanna, Justyna Marcickiewicz, Adela Bogdańska, Wiktoria Błażejewska, Monika Szulińska · 2026 · Journal of Clinical Medicine
Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation
Tahmid Hussain, Jabed Al Faysal, Pareeta Kotecha, Ronald Ramon, Yehua Wang, Jingchuan Guo, Md Mahmudul Hasan · 2026 · Diabetes Obesity and Metabolism
Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder: A Narrative Review of Available Clinical Evidence
Mette Kruse Klausen, Anders Fink‐Jensen · 2026 · Biological Psychiatry
Effectiveness of pharmacotherapies for diabetes on nicotine, food, and water intake in insulin-resistant rats
Sebastian Ortegon, Priscilla Giner, Bryan Cruz, Luis M. Carcoba, Benjamin L. Clapp, Deborah J. Clegg, Laura E. O’Dell · 2024 · Advances in Drug and Alcohol Research
NEWLY-EMERGING SIDE EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE USAGE ASSOCIATED WITH WEIGHT LOSS TREATMENT
Paula Bieganek, Bartosz Sadłowski, Stanisław Łukaszewicz, Piotr Pawłowski, Julia Rybak, Jakub Kordialik, Julia Koćwin, Sandra Sarnacka, Michał Piotr Tokarski, Angelika Banasiak · 2024 · Health Problems of Civilization
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes
Lidiya Kukova, Kashif M. Munir, Ahmed Sayeed, Stephen N. Davis · 2024 · Expert Opinion on Drug Metabolism & Toxicology
Six-year follow-up of an abstinence-based, food addiction recovery approach to weight management
Susan Peirce Thompson, Nadia Briones, Aaron K. Blumkin, Betty Rabinowitz · 2025 · Frontiers in Psychiatry
Metabolic resilience: liraglutide’s potential in alleviating depressive symptoms
Omar Gammoh, Esam Y. Qnais, Alaa A. A. Aljabali, Taher Hatahet, Abdelrahim M. Alqudah · 2025 · Molecular Biology Reports
Modulation of the Incretin Axis (GLP-1/GIP) in Behavioral Compulsions: A New Neuropsychopharmacology Frontier
Luís Jesuíno de Oliveira Andrade, Luís Matos de Oliveira, Gabriela Correia Matos de Oliveira, Ricardo Almeida Sinay Neves · 2026 · Research Square
Effects of metformin on binge‐like ethanol drinking and adenosine monophosphate kinase signaling in inbred high drinking in the dark line 1 mice
Kolter B. Grigsby, Jonathan Palacios, Amy E. Chan, Sade M. Spencer, Angela Renee Ozburn · 2024 · Alcoholism Clinical and Experimental Research
Food addiction and associated factors in newly diagnosed patients with schizophrenia: a cross-sectional comparison with siblings and healthy controls
Feten Fekih‐Romdhane, Youssef Boukadida, Abir Hakiri, Wided Homri, Majda Cheour, Souheil R. Hallit · 2025 · Journal of Eating Disorders
The gut and heart’s role in reward processing
Minel Arinel, Karim Abdelaal · 2025 · Frontiers in Integrative Neuroscience
Mood Disorders, Metabolic Bariatric Surgery, and Weight Loss Pharmacotherapy: a Research Update
Margherita Barbuti, Francesco Weiss, Giulio Perugi · 2025 · Current Obesity Reports
Glucagon-Like Peptide-1 Receptor Agonists: A Novel Indication for Substance Use Disorders?
Farage Ftiha, Joey Ftiha, Manish A. Parikh, William H. Frishman, Stephen J. Peterson · 2025 · Cardiology in Review
Addiction in Gastrointestinal and Liver Disorders
Sasha Deutsch‐Link, Isabelle S. Byers, Hyundam Gu, Juan Pablo Arab · 2026 · The American Journal of Gastroenterology
Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials
Kaitlin R. McManus, Lara A. Ray · 2026 · Expert Review of Clinical Pharmacology
GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia
Gaurab Bhaduri, Shatavisa Mukherjee, Rakesh M Parikh, Sriparna Karak, Jyotirmoy Pal · 2026 · Endocrine
Exendin-4 enhances GLP-1 signaling and reduces anxiety-like behaviors in male heroin withdrawal mice
Yang Xiang, Xiaowei Yan, Rongrong Li, Chunlu Li, Dan Yin, Cancan Luo, Yingqi Xiong, Yan Hong, Yixin Li, Baijuan Xia · 2026 · PLoS ONE
GLP-1 receptor agonists are associated with reduced nicotine dependence in hidradenitis suppurativa: A TriNetX new-user, active-comparator study
Nuran C. Golbasi, Shari R. Lipner · 2026 · JAAD International
National Institute on Drug Abuse (NIDA) clinical trials network (CTN) stimulant use disorder (StUD) task force results: 2024 update
Chatnapha Kittirattanapaiboon, STEVEN J. SHOPTAW, Taryn L. Mayes, Manish K. Jha, Udi E. Ghitza, Madhukar H. Trivedi · 2026 · Journal of Substance Use and Addiction Treatment
Preclinical and Emerging Clinical Evidence Supporting the Translational Potential of GLP-1 Receptor Agonists for Treating Psychostimulant and Nicotine Use Disorders
Rae J. Herman, Antonia Caffrey, Austin Pothikamjorn, Xinming Zhang, Ricardo Petrilli Fortuna, Heath D. Schmidt · 2026 · Biological Psychiatry
Searching for New Pharmacological Treatments of Alcohol Use Disorder (AUD): Focus on GLP–1 Receptor Agonists
Jolanta Barbara Zawilska, Ewa Zwierzyńska, Jakub Wojcieszak · 2026 · International Journal of Molecular Sciences
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Sean Woo, Grace Zhu, Chrismely Castro, Allen Phuong, Aadita Roy, Christal N. Davis, Henry R. Kranzler · 2026 · Alcoholism Clinical and Experimental Research
GLP-1 receptor agonists at the crossroads of obesity and addiction: A review of shared neurobiology and translational evidence
Simone Lista, Martina Ballerio, Susana López‐Ortiz, Kayvan Khoramipour, Bruno Pietro Imbimbo, Alejandro Santos‐Lozano, Piercarlo Minoretti, Enzo Emanuele · 2026 · Pharmacology Biochemistry and Behavior
Comparison of prohormone processing prediction using different artificial intelligence algorithms
Bruce R. Southey, Jonathan V. Sweedler, Sandra L. Rodriguez‐Zas · 2026 · In Silico Research in Biomedicine
Glucagon-like peptide-1 receptor agonist and post-operative opioid consumption in gynecologic surgery
Paula Mateo-Kubach, Gemma Mancebo, Kamilla Luca Dávid, Kyrstin Christensen, María Clara Santía, Tommaso Meschini, Heng‐Cheng Hsu, Alan P. Pan, Emily C. Rutledge, Pedro Tomas Ramirez · 2026 · International Journal of Gynecological Cancer
Glucagon‐like peptide‐1 receptor agonist use and violent crime among US adults
Daniel C. Semenza, Christopher Thomas · 2026 · Criminology
Food noise: A theoretical review
Fiona Wylie, Mehmet Kibris Mahmut, Heather Francis, Terry Davidson, Richard James Stevenson · 2026 · Appetite
Nutrition and addiction - are they linked in de-addictive process?
K S Rashmi, Liegelin Kavitha Bernhardt, Poulomi Chatterjee, Aparna Tripathy, Ashwin R Rai, Pratik Kumar Chatterjee · 2022 · International Journal of Health Sciences
Serendipity (and Clinical Observation) Strike Again: GLP-1 Receptor Agonists
Andrew Alan Nierenberg · 2023 · Psychiatric Annals
Benefits of GLP-1 Agonist
2023 · DHR Proceedings
Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders
Riccardo Dalle Grave · 2024 · IJEDO
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Saqer S. Alotaibi, Essam Hassan Eldrehmy, Sarah M. Albogami, Adel Qlayel Alkhedaide, Omima Dahab · 2025 · Experimental and Therapeutic Medicine
New directions in childhood obesity treatment – A path forward or wishful thinking?
Jessica L. Reilly, Shruthi Arora, Kelsey Chatman, Zenobia Cooper, Daniel S. Hsia · 2025 · Journal of clinical lipidology
Semaglutide: A Promising Treatment for Alcohol Use Disorder
Chelsi Patton, Amanda E. Brooks, Benjamin D. Brooks, Karma McKelvey · 2023 · Preprints.org
Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Psychiatric Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists (Glp-1 RAs) Exposure
Yao Yao, Lin Chen, Xiaohong Chen, Xiaojiang Tian, Wei Jie Zhou · 2024 · SSRN Electronic Journal
Tirzepatide attenuates dopamine reward signaling and suppresses alcohol drinking and relapse-like behaviors in rodents
Christian E. Edvardsson, Louise Adermark, Sam Gottlieb, Safana Alfreji, Thaynnam Arcebispo Emous, Yomna Gouda, Annika Thorsell, Milica Vujičić, Cajsa Aranäs, Anna Benrick et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
The emerging role of GLP-1 analogs in weight control
Silvio Stafi Filho, Isabeli Comby, Lorena Rocha Garcez, Thomas Andrade Moreira, Thalita de Oliveira Braga, Simone Carvalhaes De Miranda, Gabriela Alves Bento E Silva, Thalyson Eduardo Effgen Quartezani · 2024 · Brazilian Journal of Health Review
Investigating incretins: a review of the use of GLP-1 and GIP receptor agonists for weight loss
Amy Miller · 2024 · Journal of Aesthetic Nursing
Neurological Aspects of Substance Use Disorder: An Introduction
Justin C. McArthur, Derek W. Stitt · 2024 · Seminars in Neurology
Taming the hunger hormones
Alice Butzlaff, Dorothy James Moore · 2024 · Nursing Made Incredibly Easy!
Extraglycemic Effects of SGLT2i/GLP1-ra: A Topic Update
Uazman Alam · 2024 · Clinical Therapeutics
How the US National Institutes of Health is confronting health threats in a changing world
Jeanne Marisa Marrazzo, Kathleen Maletic Neuzil, Monica M. Bertagnolli · 2024 · The Lancet
Commentary on Qeadan et al .: Leveraging opportunities to expand the substance use disorder treatment arsenal
Ty S. Schepis · 2024 · Addiction
D’une longue pénurie thérapeutique au triomphe des nouvelles classes d’antidiabétiques dans des maladies non métaboliques
S. Halimi · 2025 · Médecine des Maladies Métaboliques
Anaesthesia’s Hobson’s choice: The brave new world of glucagon-like peptide-1 receptor agonists (GLP-1RAs)
Douglas F. Hacking, Sara Baqar, Rhys Vaughan, Alexander Craven · 2025 · Anaesthesia and Intensive Care
The use of tirzepatide to successfully treat persistent genital arousal disorder/genitopelvic dysesthesia: a case report
Eliza F. Burr, Maya Roytman, Évéline Poirier, Marta T. Kolbuszewska, James G. Pfaus, Barry R. Komisaruk, Irwin Goldstein, Rachel S. Rubin · 2025 · Sexual Medicine
Decision-Making Scores and Hunger Susceptibility: A Positive Correlation Mediated by Fasting FGF21 Independently of Body Fat
Andrés M. Treviño‐Alvarez, Tomás Cabeza de Baca, Emma J. Stinson, Hannah T. Fry, Marci E. Gluck, Douglas C. Chang, Paolo Piaggi, Jonathan A. Krakoff · 2025 · Nutrients
A current grasp of GLP-1 receptor agonists for addiction: emerging therapeutic potential
RM Moosa-Battey · 2025 · SA pharmaceutical journal.
Association of Patient Cost-Sharing With Adherence to GLP-1a and Adverse Health Outcomes
Zhang, Donglan, Gencerliler, Nihan, Mukhopadhyay, Amrita, Blecker, Saul, E. Grams, Morgan, Wright, Davene R., Hsing-Chun Wang, Vivian, Rajan, Anand, Butt, Eisha, Shin, Jung-Im et al. · 2025 · Figshare
Glucagon-like peptide-1 receptor agonists after recent burn injury are associated with lower rates of infection, mortality, and opioid prescriptions
Matthew Q Dao, Anika Y. Kim, Sarah Wang, Paul Won, Matteo Laspro, T. Justin Gillenwater, Haig A Yenikomshian, Maxwell B Johnson · 2025 · Burns
Impact of Preoperative Glucagon-Like Peptide-1 Receptor Agonist Use on Short-Term and Long-Term Outcomes Following Thoracic and/or Lumbar Fusion for Spinal Deformity: A BMI-Stratified Cohort Study
Harmon Singh Khela, Arman Kishan, Alex Hernandez Manriquez, Lachlan Kirby, Zvipo Mutsa Chisango, Nicolas L. Carayannopoulos, Manjot Singh, Ethan J. Cottrill, Raffi S. Avedian, Christopher J. Kleck et al. · 2026 · Spine Open